

FcRn and Neuromuscular Disease

presented by

Daniel DiCapua, MD

4/10/2025 8:00:00 AM

**Zoom & In Person (Contact Activity Coordinator or
sponsoring department for more information)**

Learning Objectives: *As a result of participating in this Live Activity, participants should be able to:*

- 1 What is the FcRn and why are we talking about it?*
- 2 Discuss drugs that inhibit FcRn including: efgartigimod, rozanolixizumab, batoclimab, and nipocalimab*
- 3 Review trials for MG and CIDP that led to current FDA approvals*
- 4 Discuss potential future uses of FcRn inhibitors in neurologic disease*

Accreditation Statement: In support of improving patient care, Hartford HealthCare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit Designation Statement: Hartford Healthcare designates this Live Activity for 1.00 AMA PRA Category 1 Credit(s)[™]. Physicians should only claim credit commensurate with their participation.

Financial Disclosures:

- Daniel DiCapua, MD : Advisor-CSL Behring, LLC (Relationship has ended)|Speakers Bureau-argenx (Relationship has ended)|Advisor-argenx (Relationship has ended)|Advisor-Grifols (Relationship has ended)|Advisor-Alexion Pharmaceuticals (Relationship has ended) - 04/01/2025



JOINTLY ACCREDITED PROVIDER[™]
INTERPROFESSIONAL CONTINUING EDUCATION